ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- 1 September 2021
- journal article
- aggressive b-cell-lymphoma
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 21, S377-S378
- https://doi.org/10.1016/s2152-2650(21)01861-9